DEF: Shuttle Pharma 2026 Proxy: Reverse Split Proposal

Shuttle Pharmaceuticals Holdings, Inc. seeks shareholder approval for a reverse stock split of up to 1-for-150 to maintain Nasdaq listing compliance.

Summary

• The 2026 Annual Meeting is scheduled for May 21, 2026, in a virtual-only format.
• Shareholders will vote on the election of five directors, ratification of Forvis Mazars, LLP as auditors, and advisory approval of executive compensation.
• A key proposal seeks authorization for the Board to effect one or more reverse stock splits at a cumulative ratio between 1-for-2 and 1-for-150.
• The company aims to maintain Nasdaq minimum bid price requirements amid uncertain market conditions.
• The company has 5,546,309 shares of common stock outstanding as of the March 25, 2026 record date.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a defensive filing necessitated by persistent financial distress, evidenced by the need for a massive reverse stock split authorization and high executive turnover.

Positives

• The company is proactively seeking flexibility to maintain its Nasdaq listing through the proposed reverse stock split authorization.
• The Board has adopted a clawback policy to comply with federal securities laws regarding incentive compensation.
• The company has successfully transitioned to a virtual meeting format to improve accessibility and reduce costs.

Negatives

• The company has a history of needing reverse stock splits to maintain Nasdaq compliance, having executed splits in August 2024 and June 2025.
• The proposed reverse stock split ratio of up to 1-for-150 indicates significant downward pressure on the share price.
• The company has experienced high turnover in executive leadership, including the resignation of the former CEO, CFO, and President/COO in 2025.

Risks

• Potential delisting from the Nasdaq Capital Market if minimum bid price requirements are not met.
• The reverse stock split may not result in a sustained increase in the share price and could be viewed negatively by investors.
• Reduced liquidity and trading volume following a reverse stock split.
• The company may need to conduct further equity offerings to fund clinical trials, which could be dilutive to existing shareholders.

Future Outlook

The company intends to use the requested reverse stock split authority to maintain Nasdaq listing compliance and to retain flexibility for future capital raising activities to fund clinical trials.

Management Comments

• We are seeking this flexibility to assist the Company in weathering the current uncertain market conditions.
• We believe that conducting the Reverse Stock Split, and then having additional availability to conduct a further reverse stock split if needed, is in the best interest of the Company and its stockholders.

Industry Context

StockSavvy.ai notes that Shuttle Pharmaceuticals is facing common challenges for small-cap biotech firms, specifically the struggle to maintain Nasdaq listing requirements while managing cash burn and leadership transitions.

Comparison to Industry Standards

• The use of reverse stock splits to maintain Nasdaq compliance is a common, albeit often dilutive, strategy among micro-cap biotech companies.
• The company's governance structure, including the use of independent directors and standing committees, aligns with standard practices for Nasdaq-listed entities.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• The company issued a $250,000 promissory note to a former officer in 2024, which was fully repaid by December 31, 2025.
• The company issued a $250,000 convertible note to the former CEO in 2024, which was converted into 39,216 shares in October 2025.
• The company entered into a $75,000 loan agreement with the former CEO in March 2025, which was repaid in full on March 25, 2026.

Stakeholder Impact

• Shareholders face potential dilution and the negative optics of a significant reverse stock split.
• The company's ability to maintain Nasdaq listing is critical for liquidity and institutional investor interest.

Next Steps

• Hold the Annual Meeting of Stockholders on May 21, 2026.
• Implement reverse stock split if approved and deemed necessary by the Board.
• File results of the Annual Meeting on Form 8-K within four business days.

Key Dates

Recommendation

The company's reliance on repeated reverse stock splits to maintain listing, combined with high executive turnover and the stated need for future capital raises, indicates significant financial instability and risk for long-term investors.

Keywords

Shuttle Pharmaceuticals, SHPH, reverse stock split, Nasdaq, proxy statement, biotech, clinical trials